Enjoy complimentary customisation on priority with our Enterprise License!
The prils market size is forecast to increase by USD 596.3 million, at a CAGR of 4.2% between 2023 and 2028. The market is witnessing significant growth due to the increasing prevalence of chronic conditions such as high blood pressure, chronic heart diseases, and chronic kidney diseases among the older population. This demographic shift is driving the demand for effective treatments and medications, particularly in the areas of biotechnology and healthcare. The development of new drugs and therapies is a key trend in the market, as companies seek to address the unmet needs of patients and improve health outcomes. However, the market also faces challenges, including the potential side effects of certain medications and the growing issue of sedentary lifestyles, which can exacerbate health conditions and reduce the efficacy of treatments. To stay competitive, industry players must focus on innovation, regulatory compliance, and patient-centric approaches to care. By addressing these trends and challenges, the market is poised for continued growth and success.
The market has witnessed a notable shift towards the development of PRILs (Protein Receptor-Activated Inhibitors of the Angiotensin System) as potential therapeutic solutions for chronic diseases, particularly heart disease and kidney failures. PRILs, a class of antihypertension drugs, have demonstrated significant benefits in managing high blood pressure, hypertension, and associated complications such as stroke and heart attack. PRILs have gained popularity due to their unique mechanism of action, which involves inhibiting the renin-angiotensin-aldosterone system (RAAS). This system plays a crucial role in regulating blood pressure and fluid balance in the body. By targeting this system, PRILs offer a more comprehensive approach to managing chronic diseases. The biotech sector has been instrumental in the advancement of PRILs. Biotechnological innovations have enabled the production of PRILs through recombinant DNA technology, ensuring a consistent and reliable supply. The use of PRILs in pharmaceutical applications has been a game-changer, as they offer several advantages over traditional antihypertension drugs. PRILs have shown therapeutic properties in managing chronic diseases, including heart diseases and kidney diseases. Benazepril, cilazapril, quinapril, and ramipril are some of the PRILs that have gained FDA approval for use.
These drugs have been proven effective in managing high blood pressure and reducing the risk of complications such as stroke and heart attack. The older population is particularly vulnerable to chronic diseases, making PRILs an essential tool in addressing this health concern. PRILs have been shown to improve the quality of life for patients, reducing the risk of hospitalization and improving overall health outcomes. The application of PRILs extends beyond human health. In the agricultural sector, PRILs have been used to manage urea, ammonia, and biuret levels in dairy and beef cattle. This application has led to improved animal health and productivity, making PRILs an essential tool in the livestock industry. In conclusion, PRILs represent a significant advancement in the pharmaceutical industry, offering a more comprehensive approach to managing chronic diseases. The biotech sector's role in the development and production of PRILs has been instrumental in making these drugs accessible and effective. Their therapeutic properties make them an essential tool in managing chronic diseases, particularly heart diseases and kidney diseases, in both human and animal health.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The hypertension segment is estimated to witness significant growth during the forecast period. The older population in the United States continues to grapple with chronic health conditions such as high blood pressure, chronic heart diseases, and kidney disorders. Pharmaceutical companies have responded with innovative solutions, including the use of ACE inhibitors for managing hypertension. These biotechnological advancements, represented by drugs like ramipril, quinapril, benazepril, and cilazapril, function by modifying the renin-angiotensin system. Specifically, they inhibit the production of angiotensin II, a substance that narrows blood vessels, thereby reducing blood pressure.
Get a glance at the market share of various segments Download the PDF Sample
The hypertension segment was valued at USD 1.04 billion in 2018. Furthermore, these medications promote the excretion of sodium through urine. The use of ACE inhibitors in healthcare settings has proven effective in preventing hospitalization for individuals with hypertension and reducing the risk of heart failure-related mortality. However, the segment faces challenges, including the increasing preference for Angiotensin II receptor blockers (ARBs) among healthcare providers. Despite these hurdles, the demand for ACE inhibitors is expected to persist due to their proven efficacy in managing cardiovascular conditions.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In the US and North America, the market for therapeutics targeting Angiotensin-Converting Enzyme (ACE) is experiencing significant growth due to the high prevalence of heart diseases and kidney diseases. The US is a significant contributor to this market, with its large population and high incidence of heart failure. The economic burden of heart failure is substantial, making the development and consumption of effective treatments a priority. The healthcare sector in North America invests heavily in research and development, ensuring a steady supply of innovative treatments for heart diseases. The high prevalence rate of heart diseases and the availability of generic drugs further boost the market growth in the region.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rising geriatric population is notably driving market growth. The market is experiencing notable growth due to the escalating prevalence of age-related health issues, particularly antihypertension conditions, among the geriatric population. With an increasing number of older adults, there is a corresponding rise in the demand for prils, a class of medications known as angiotensin-converting enzyme (ACE) inhibitors. These drugs are commonly prescribed to manage conditions such as hypertension, stroke, and heart attack, which are more prevalent among the elderly.
This demographic trend is particularly significant in regions like Asia-Pacific and Europe, where the elderly population is expanding rapidly. Furthermore, the growing awareness of the importance of managing chronic conditions to enhance quality of life and decrease healthcare expenses adds to the market's demand. The prils market is a crucial sector in the healthcare industry, providing essential medications to help mitigate the risks associated with age-related cardiovascular diseases and chronic kidney disorders. Thus, such factors are driving the growth of the market during the forecast period.
The development of new drugs is the key trend in the market. The market is experiencing a notable shift towards the creation of innovative drugs, fueled by advancements in medical research and technology. Biotech firms are prioritizing the development of improved angiotensin-converting enzyme (ACE) inhibitors to combat the rising incidence of heart disease and kidney failures, particularly among the elderly population.
Enhancements in drug formulation and delivery methods are boosting the efficacy and patient adherence to Prils treatments. For example, the incorporation of artificial intelligence and machine learning in drug discovery processes is expediting the identification of new compounds and optimizing clinical trials. Moreover, strategic partnerships and acquisitions are essential for companies to broaden their offerings and capitalize on each other's strengths. Thus, such trends will shape the growth of the market during the forecast period.
Side effects of prils is the major challenge that affects the growth of the market. Smoking and certain health conditions, such as dairy cattle, beef cattle, sheep, and goat rearing, necessitate the use of drugs like urea, ammonia, biuret, and those in the ACE inhibitor class, such as benazepril and ramipril, for managing diseases like hypertension and heart failure. However, these medications come with side effects that can impact patient compliance. Side effects include dizziness, ringing or buzzing in the ears, diarrhea, high potassium levels in the blood, and swelling due to fluid retention. These negative impacts may discourage patients from using these drugs, leading to an alternative approach to disease management through lifestyle modifications, including proper diets and exercise.
This trend poses a challenge for the market growth of these drugs during the forecast period. It is essential for healthcare professionals to educate patients about the importance of adhering to their medication regimen while also emphasizing the benefits of maintaining a healthy lifestyle. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aurobindo Pharma Ltd. - The company offers prils such as Ramipril capsules that are available in 1.25mg, 5mg and 10mg.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses a range of therapeutic agents derived from biotech sources, primarily used in the pharmaceutical industry to treat various chronic diseases. These APIs, or active pharmaceutical ingredients, exhibit therapeutic properties for heart disease, hypertension, and kidney failures, among others. The older population is a significant consumer base due to the high prevalence of chronic diseases such as high blood pressure, chronic heart diseases, and kidney disorders. The healthcare sector's increasing focus on cost-effective solutions has led to the popularity of PRILs, including ramipril, quinapril, benazepril, and cilazapril. These drugs work by inhibiting the angiotensin-converting enzyme (ACE), which plays a crucial role in regulating blood flow and blood pressure.
The market is driven by the growing burden of cardiovascular diseases, including heart failure, stroke, and heart attack, as well as the rising prevalence of sedentary lifestyles and unhealthy diets. The market is also influenced by the increasing availability of generic drugs and healthcare centres, which offer affordable alternatives to branded medications. However, challenges such as the proliferation of fake medications and the high costs of drugs remain significant barriers to market growth. The market is expected to witness significant growth due to the increasing geriatric population, the rising prevalence of smoking, and the growing awareness of the importance of managing chronic diseases to maintain overall health.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
158 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.2% |
|
Market Growth 2024-2028 |
USD 596.3 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.0 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
China, US, India, Germany, Canada, Japan, UK, Mexico, France, and Italy |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Aurobindo Pharma Ltd., Cipla Inc., Deafarma Srl, Dr Reddys Laboratories Ltd., Farmhispania Group, Fazio Group of Companies, Glenmark Pharmaceuticals Ltd., Hiral Labs Ltd., Lupin Ltd., Manus Aktteva Biopharma LLP, Melody Healthcare, Merck KGaA, Neuland Laboratories, Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Zhejiang Changming Pharmaceutical Co. Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Five Forces Analysis
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
